**Suppl. Table 1. Details of microvascular status in the 3 cohorts**

|  | **CORONADO study** | | | **ABCD COVID-19 diabetes national audit** | | | **AMERICADO study** | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **All (n=2,713)** | **no MICRO (n = 304)** | **any MICRO (n = 1,010)** | **All (n=3,038)** | **no MICRO (n = 750)** | **any MICRO (n = 1,059)** | **All (n=7,367)** | **no MICRO (n = 5,567)** | **any MICRO (n = 1,800)** |
| Diabetic retinopathy (DR) |  |  |  |  |  |  |  |  |  |
| DR | 312 (12%) | 0 (0%) | 275 (27%) | 547 (18%) | 0 (0%) | 424 (40%) | 903 (12%) | 0 | 903 (50%) |
| No DR | 1798 (66%) | 304 (100%) | 735 (73%) | 1580 (52%) | 750 (100%) | 635 (60%) | 6464 (88%) | 5567 (100%) | 897(50%) |
| not ascertained | 603 (22%) | 0 (0%) | 0 (0%) | 911 (30%) | 0 (0%) | 0 (0%) | - | - | - |
| Diabetic kidney disease (DKD) |  |  |  |  |  |  |  |  |  |
| DKD | 1183 (44%) | 0 (0%) | 931 (92%) | 1367 (45%) | 0 (0%) | 932 (88%) | 1121 (15%) | 0 | 1121 (62%) |
| no DKD | 451 (17%) | 304 (100%) | 79 (8%) | 1124 (37%) | 750 (100%) | 127 (12%) | 6246 (85%) | 5567 (100%) | 679 (38%) |
| not ascertained | 1079 (40%) | 0 (0%) | 0 (0%) | 547 (18%) | 0 (0%) | 0 (0%) | - |  |  |
| Diabetic foot ulcer (DFU) |  |  |  |  |  |  |  |  |  |
| DFU | 185 (7%) | 0 (0%) | 124 (13%) | 182 (6%) | 0 (0%) | 159 (15%) | 336 (5%) | 0 | 336 (19%) |
| no DFU | 2414 (89%) | 346 (100%) | 844 (87%) | 1914 (63%) | 750 (100%) | 900 (85%) | 7031 (95%) | 5567 (100%) | 1464 (81%) |
| not ascertained | 114 (4%) | 0 (0%) | 0 (0%) | 972 (32%) | 0 (0%) | 0 (0%) |  |  |  |
| Albuminuria |  |  |  |  |  |  |  |  |  |
| Normal | 484 (18%) | 207 (68%) | 190 (18%) | - | - | - | - | - | - |
| Moderately increased | 318 (12%) | 97 (32%) | 186 (18%) | - | - | - | - | - | - |
| Severely increased | 131 (5%) | 0 (0%) | 123 (12%) | - | - | - | - | - | - |
| not available | 1780 (66%) | 0 (0%) | 511 (52%) | - | - | - | - | - | - |
| Altered renal function |  |  |  |  |  |  |  |  |  |
| No | 1501 (55%) | 304 (100%) | 112 (11%) | - | - | - | - | - | - |
| Yes | 1148 (43%) | 0 (0%) | 898 (89%) | - | - | - | - | - | - |
| not available | 64 (2%) | 0 (0%) | 0 (0%) | - | - | - | - | - | - |

## Data are n (%). DR (Diabetic retinopathy) active or past DR. DKD, diabetic kidney disease, defined as proteinuria (when available) and/or eGFR<60 ml/min/1.73m2. DFU, active or past diabetic foot ulcer (see definitions in Methods). Altered renal function, defined as eGFR<60 ml/min/1.73 m2. Of note, in the AMERICADO study, microvascular burden was defined using billing codes, so that patients with no microvascular billing codes were considered as not affected (no MICRO) leaving no patient with a “not ascertained” status.